AmbAgon Therapeutics is a technology company.
AmbAgon Therapeutics has raised $85.0M across 1 funding round.
AmbAgon Therapeutics has raised $85.0M in total across 1 funding round.
AmbAgon Therapeutics has raised $85.0M in total across 1 funding round.
AmbAgon Therapeutics's investors include Nextech Invest.
AmbAgon Therapeutics is a biotechnology company developing first-in-class small-molecule therapeutics that stabilize 14-3-3 protein interactions with oncogenic proteins, primarily targeting breast cancer and expanding to other undruggable targets in oncology, metabolic disorders, neurodegeneration, and infectious diseases.[1][2][3] The company serves patients with hard-to-treat cancers by augmenting the tumor-suppressing functions of the 14-3-3 protein through "molecular glues"—a novel platform addressing intrinsically disordered proteins previously considered undruggable—solving the challenge of inhibiting oncogenic transcription factors that have eluded industry efforts for over 20 years.[1][3][4] Founded in 2020 and based in San Carlos, California, AmbAgon raised $18 million in seed funding in July 2020 and $85 million in Series A in January 2022, supporting platform expansion, five ongoing projects (including one partnered with AbbVie), and a team of 18 employees with expertise in 14-3-3 structural biology.[4]
AmbAgon Therapeutics was founded in 2020 by Christian Ottmann and Luc Brunsveld from Eindhoven University of Technology, and Michelle Arkin from the University of California San Francisco, who are global leaders in 14-3-3 structural biology and protein-protein interactions.[1][2][4] The idea emerged from their academic labs, where they pioneered chemical approaches to stabilize 14-3-3 interactions with oncogenic transcription factors, enabling inhibition of "undruggable" targets in breast cancer—a gap in therapeutics for two decades.[1][4] Early traction came swiftly: the company launched with substantial seed and Series A funding totaling over $100 million, recruited industry-experienced leadership like CEO Sean Clarke (post-liquidity event from a prior venture), and advanced multiple projects, including a cancer program partnered with AbbVie.[4]
AmbAgon's platform stands out in biotech through these key strengths:
AmbAgon rides the molecular glues and protein degradation wave, expanding the druggable proteome to intrinsically disordered proteins (IDPs)—a class evading traditional small-molecule drugs but implicated in 80% of cancer-linked proteins.[3][4] Timing is ideal amid surging interest in targeted protein stabilization post successes like PROTACs, with biotech funding favoring platforms tackling undruggable targets amid a post-2022 recovery in early-stage oncology investment.[4] Market forces like rising cancer incidence, unmet needs in breast cancer transcription factor inhibition, and partnerships (e.g., AbbVie) bolster its position, while its academic-to-industry translation influences the ecosystem by validating 14-3-3 as a versatile hub for novel therapies beyond degradation.[1][4]
AmbAgon is poised to advance its lead programs into preclinical stages, leveraging Series A funds to expand beyond oncology into neurodegeneration and beyond, with AbbVie partnership de-risking one asset toward clinical trials.[4] Trends like AI-driven drug discovery and IDP targeting will accelerate its platform, potentially yielding first-in-class stabilizers by 2027-2028 if hit-to-lead optimization succeeds. Its influence could grow by pioneering 14-3-3 modulation as a new modality, transforming undruggable targets into viable pipelines and attracting Big Pharma buyouts—echoing its mission to aggressively expand medicine's boundaries for uncured diseases.[2][3]
AmbAgon Therapeutics has raised $85.0M across 1 funding round. Most recently, it raised $85.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $85.0M Series A | Nextech Invest |